BAK1 and hyperemia: The latanoprost without BAK treatment arm had numerically more patients with eye pain, conjunctival hyperemia, and eye pruritis versus the latanoprost with BAK treatment group (n=185 vs n=136, n=58 vs n=55, and n=16 vs n=14, respectively).